Last reviewed · How we verify
PEG-rhG-GSF
PEG-rhG-CSF is a pegylated recombinant human granulocyte colony-stimulating factor that stimulates the production and release of neutrophils from bone marrow to increase white blood cell counts.
PEG-rhG-CSF is a pegylated recombinant human granulocyte colony-stimulating factor that stimulates the production and release of neutrophils from bone marrow to increase white blood cell counts. Used for Chemotherapy-induced neutropenia (CIN), Severe chronic neutropenia, Peripheral blood progenitor cell mobilization.
At a glance
| Generic name | PEG-rhG-GSF |
|---|---|
| Also known as | Polyethylene glycolylated recombinant human granulocyte stimulating factor |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) analog |
| Target | G-CSF receptor (GCSFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Hematology |
| Phase | Phase 3 |
Mechanism of action
This drug is a long-acting formulation of G-CSF created by conjugating polyethylene glycol (PEG) to recombinant human granulocyte colony-stimulating factor. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to non-pegylated G-CSF. It binds to G-CSF receptors on hematopoietic progenitor cells, promoting their proliferation, differentiation, and mobilization into peripheral blood.
Approved indications
- Chemotherapy-induced neutropenia (CIN)
- Severe chronic neutropenia
- Peripheral blood progenitor cell mobilization
Common side effects
- Bone pain
- Fever
- Fatigue
- Headache
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |